BioScrip Inc. (BIOS)

2.77
0.07 2.40
NASDAQ : Health Services
Prev Close 2.70
Open 2.69
Day Low/High 2.69 / 2.77
52 Wk Low/High 1.80 / 3.39
Volume 435.15K
Avg Volume 540.30K
Exchange NASDAQ
Shares Outstanding 127.95M
Market Cap 344.19M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioScrip Provides Update On Annual Form 10-K Filing Status

BioScrip Provides Update On Annual Form 10-K Filing Status

BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that it will be filing a Form 12b-25 with the U.

BioScrip Reports Fourth Quarter And Full Year 2017 Financial Results

BioScrip Reports Fourth Quarter And Full Year 2017 Financial Results

BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced its preliminary 2017 financial results and provided...

BioScrip Schedules Release Of Fourth Quarter And Full Year 2017 Financial Results And Conference Call

BioScrip Schedules Release Of Fourth Quarter And Full Year 2017 Financial Results And Conference Call

BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that the Company will issue its financial results press...

BIOS: Insiders Vs. Shorts

BIOS: Insiders Vs. Shorts

The most recent short interest data was recently released for the 01/31/2018 settlement date, and BioScrip Inc is one of the most shorted stocks of the Russell 3000, based on 12.29 "days to cover" versus the median component at 4.26. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

BioScrip Announces U.S. Congress Passage Of Medicare Home Infusion Transition Benefit, Effective 2019

BioScrip Announces U.S. Congress Passage Of Medicare Home Infusion Transition Benefit, Effective 2019

BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that the U.

Commit To Buy BioScrip At $2.50, Earn 23.9% Annualized Using Options

Commit To Buy BioScrip At $2.50, Earn 23.9% Annualized Using Options

Investors considering a purchase of BioScrip Inc stock, but cautious about paying the going market price of $2.99/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July put at the $2.50 strike, which has a bid at the time of this writing of 30 cents.

BioScrip Announces Additions To Senior Leadership Team

BioScrip Announces Additions To Senior Leadership Team

Appoints Harriet Booker as Senior Vice President, Chief Operating Officer and Danny R. Claycomb as Senior Vice President, Revenue Cycle Management

BIOS: Insiders vs. Shorts

BIOS: Insiders vs. Shorts

The most recent short interest data was recently released for the 10/31/2017 settlement date, and BioScrip Inc is one of the most shorted stocks of the Russell 3000, based on 18.82 "days to cover" versus the median component at 5.18. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Short Interest Drops 11.6% For BIOS

Short Interest Drops 11.6% For BIOS

The most recent short interest data has been released for the 08/31/2017 settlement date, which shows a 2,458,477 share decrease in total short interest for BioScrip Inc , to 18,783,163, a decrease of 11.57% since 08/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

BioScrip Applauds US House Passage Of HR3178, The Medicare Part B Improvement Act Of 2017

BioScrip Applauds US House Passage Of HR3178, The Medicare Part B Improvement Act Of 2017

Legislation Accelerates Medicare Payment of Home Infusion Therapy Services to 2019

BioScrip Announces New Senior Note Facilities

BioScrip Announces New Senior Note Facilities

Agreement Will Immediately Improve Capital Structure, Provide Operational Flexibility, and Result in Excess of $50 million in Liquidity

BIOS Crosses Above Average Analyst Target

In recent trading, shares of BioScrip Inc have crossed above the average analyst 12-month target price of $2.40, changing hands for $2.42/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

TheStreet Quant Rating: D (Sell)